Navigation Links
Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process
Date:10/22/2008

ted proofreading solutions that enable organizations to achieve unprecedented content integrity. Major pharmaceutical companies rely on Global Vision to reduce the risk of textual or artwork errors from occurring throughout their workflow. For over a decade, Global Vision has helped clients increase inspection accuracy, speed, productivity, and process efficiencies. More information is available at http://www.globalvisioninc.com .


'/>"/>
SOURCE Global Vision, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Video: OneTouch(R) Teams With Online Diabetes Community to Launch Global Diabetes Handprint Project
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
4. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
5. Mentice Appoints Bjorn Larsson as Vice President of Global Marketing
6. International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive
7. The Plasmodium vivax genome provides new routes and challenges in the global fight against malaria
8. Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition
9. Kendle to Present at the UBS Global Life Sciences Conference
10. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
11. Boston Scientific to Participate in UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6